Evidence map›Paper›PMID 39562421›Full record

Observational studyAnnals of surgical oncology2025

Multispectral Fluorescence Imaging as a Tool to Distinguish Pelvic Lymphatic Drainage Patterns During Robot-assisted Lymph Node Dissection in Prostate Cancer.

Anne-Claire Berrens, Tessa Buckle, Matthias N van Oosterom, Leon J Slof, Pim J van Leeuwen, Esther M K Wit, Hilda A de Barros, Jakko A Nieuwenhuijzen, Elise M Bekers, Maarten L Donswijk and 2 more

Erratum issued Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05120973 (MultiSPectral fLuorescence Imaging as a Tool to Separate Healthy and Disease Related Lymphatic Anatomies During Lymph Node Dissections in Prostate Cancer.), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05120973 completednot on this map

MultiSPectral fLuorescence Imaging as a Tool to Separate Healthy and Disease Related Lymphatic Anatomies During Lymph Node Dissections in Prostate Cancer.

TypeobservationalSponsorThe Netherlands Cancer InstituteRan2021 to 2024Enrolled26ConditionsProstate CancerArmsmultispectral imaging, fluorescence for lymphatic mapping
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Anne-Claire BerrensDepartment of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. a.c.berrens@amsterdamumc.nl.ORCID http://orcid.org/0000-0002-3328-384X
Tessa BuckleDepartment of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Matthias N van OosteromDepartment of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Leon J SlofDepartment of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Pim J van LeeuwenDepartment of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Esther M K WitDepartment of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Hilda A de BarrosDepartment of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Jakko A NieuwenhuijzenDepartment of Urology, Amsterdam University Medical Center, VUmc, Amsterdam, The Netherlands.
Elise M BekersDepartment of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Maarten L DonswijkDepartment of Nuclear Medicine, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Fijs W B van LeeuwenDepartment of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Henk G van der PoelDepartment of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Funding

NWO-TTW-VICI grant 16141
6 · The paper itself

Abstract

backgroundThe invasive nature of extended pelvic lymph node dissection (ePLND) prompts the need for alternative lymphatic mapping technologies. To change the focus to "sparing nodes that are not involved," the first step is to research the feasibility of intraoperatively distinguishing the lymph drainage patterns of the prostate from healthy organs.

methodsWe performed a prospective study (NCT05120973) that included 16 patients who underwent a robot-assisted radical prostatectomy + ePLND + sentinel node (using indocyanine green-

resultsIndocyanine green and fluorescein were visible in the same regions within the ePLND-template and co-accumulated in lymph vessels in vivo. At histopathology, fluorescein was seen in only 10 of 370 lymph nodes (possibly owing to tracer properties), none of which overlapped with indocyanine green and none were tumor-positive. Administration of fluorescein did not result in discomfort or abnormal postoperative recovery.

conclusionsMultispectral imaging can be used to distinguish lymphatic drainage patterns. Our in vivo findings indicate that within the ePLND-template, lymphatic drainage patterns of the prostate at least partly overlap with those of upper leg and abdominal wall. The properties of fluorescein render it unsuitable for confirmation of fluorescence at histopathology.

Indexed as

Lymph Node ExcisionOptical ImagingProstatectomyProstatic NeoplasmsRobotic Surgical ProceduresAgedColoring AgentsFluoresceinFluorescent DyesFollow-Up StudiesHumansIndocyanine GreenLymph NodesMaleMiddle AgedPelvisColoring AgentsFluoresceinFluorescent DyesIndocyanine GreenTechnetium Tc 99m Aggregated Albumintechnetium Tc 99m nanocolloidFluorescence guided surgeryImage-guided surgeryIndocyanine greenLymphedemaLymph node dissectionProstate cancerRobot-assisted surgerySentinel node

Identifiers

PMID39562421
PMCPMC11698825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.